Core Viewpoint - AIRO Group Holdings, Inc. has announced the pricing of its upsized underwritten public offering of 4,200,000 shares at a price of $18.50 per share, indicating strong market interest and potential for capital raising [1] Company Summary - AIRO Group specializes in advanced aerospace and defense technologies, positioning itself in a growing sector with increasing demand for innovative solutions [1] - The gross proceeds from the offering are expected to be significant, although the exact amount after deducting underwriting discounts and commissions has not been specified [1]

Group 1 - Veritone, Inc. has announced the pricing of an underwritten public offering of 9,505,705 shares of its common stock at a price of $2.63 per share [1] - The aggregate gross proceeds from this offering are expected to be approximately $25 million before deducting underwriting discounts and commissions [1]

Core Viewpoint - Mineralys Therapeutics, Inc. has successfully closed a public offering of 11,274,509 shares of common stock, raising approximately $287.5 million before expenses, to fund the development of its product candidate lorundrostat and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $25.50 per share, which included the full exercise of the underwriters' option to purchase an additional 1,470,588 shares [1]. - The offering was managed by BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities, with LifeSci Capital as the lead manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for clinical development of lorundrostat, including research, development, manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related comorbidities, including chronic kidney disease and obstructive sleep apnea, driven by dysregulated aldosterone [5]. - The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [5].

Core Viewpoint - Nova LifeStyle, Inc. has successfully closed a public offering of 9,836,054 shares of common stock and 19,672,108 warrants, raising approximately $9.0 million in gross proceeds, which will be utilized for working capital, marketing, debt repayment, and capital expenditures [1][2]. Group 1: Offering Details - The public offering was priced at $0.915 per share, with each share sold together with two warrants, each exercisable at $1.098 per share [1]. - The offering closed on September 4, 2025, and the warrants will expire on the fifth anniversary of their issuance [1][2]. - The offering was conducted under a registration statement declared effective by the SEC on August 27, 2025 [4]. Group 2: Company Overview - Nova LifeStyle, Inc. is an innovative designer and distributor of modern lifestyle furniture, including sofas, dining room furniture, and office furniture, targeting middle and upper middle-income consumers [6]. - The company's product lines include the Nova Brands and Diamond Sofa, featuring urban contemporary styles that integrate comfort and functionality [6].

Core Viewpoint - Artelo Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on treating various medical conditions [1][6]. Group 1: Offering Details - The company is offering 640,924 shares of common stock at a price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The total gross proceeds from the offering are expected to be around $3.0 million before deducting underwriting discounts and other expenses [1]. - Underwriters have a 45-day option to purchase an additional 102,272 shares to cover over-allotments [1]. Group 2: Underwriting and Registration - R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering [2]. - The shares and warrants are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on July 14, 2023 [2]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6]. - The company is also implementing a digital asset treasury strategy to enhance its financial position [6].

Group 1: Offering Details - Plains All American Pipeline, L.P. has priced an underwritten public offering of $1.25 billion in debt securities, which includes $700 million of 4.70% senior unsecured notes due 2031 and $550 million of 5.60% senior unsecured notes due 2036 [1] - The offering is expected to close on September 8, 2025, subject to customary closing conditions [1] Group 2: Use of Proceeds - The proceeds from the offering, approximately $1,236.5 million after discounts and expenses, will be used to redeem the 4.65% Senior Notes due October 2025 and to fund part of the acquisition of a 55% non-operated interest in EPIC Crude Holdings, LP [2] - If the EPIC Acquisition is not completed, the remaining net proceeds will be used for general partnership purposes, including intra-group lending, repayment of indebtedness, acquisitions, capital expenditures, and working capital [2] Group 3: Transaction Conditions - The closing of the offering is not contingent upon the completion of the Redemption or the EPIC Acquisition, and vice versa [3] Group 4: Company Overview - Plains All American Pipeline is a publicly traded master limited partnership that operates midstream energy infrastructure and provides logistics services for crude oil and natural gas liquids [7] - The company owns a vast network of pipeline gathering and transportation systems, along with terminalling, storage, processing, and fractionation assets, serving key producing basins and major market hubs in the U.S. and Canada [7] - On average, the company handles over 8 million barrels per day of crude oil and natural gas liquids [7]

Core Viewpoint - Nova LifeStyle, Inc. has announced a public offering of up to 9,522,393 shares of common stock and up to 19,044,786 warrants at a price of $0.915 per share, aiming to raise approximately $8.71 million for various corporate purposes [1][2]. Group 1: Offering Details - The public offering includes common stock sold with two warrants per share, with each warrant exercisable at an exercise price of $1.098 [1]. - The offering is expected to close on or about September 4, 2025, pending customary closing conditions [2]. - Gross proceeds before expenses are estimated at approximately $8.71 million, subject to increase based on pending subscriptions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, marketing expenditures, repayment of short-term debt, and capital expenditures [2]. Group 3: Company Overview - Nova LifeStyle, Inc. is an innovative designer and distributor of modern lifestyle furniture, including sofas, dining room furniture, and office furniture, targeting middle and upper middle-income consumers [6]. - The company operates under the Nova Brands and Diamond Sofa, offering urban contemporary styles that combine comfort and functionality [6].

Core Viewpoint - Femasys Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $8.0 million to support its commercial expansion and product development efforts [2][4]. Group 1: Offering Details - The public offering consists of 10,434,586 shares of common stock and pre-funded warrants to purchase up to 11,750,000 shares, with a combined offering price of $0.36 per share and accompanying common warrant [1][2]. - The offering is expected to close on or about August 27, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - Femasys plans to utilize the net proceeds from the offering for the expansion of commercial efforts, product development, general corporate purposes, capital expenditures, and working capital [2]. Group 3: Company Overview - Femasys is a biomedical innovator focused on women's health, offering a range of in-office therapeutic and diagnostic products [6]. - The company’s fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [6]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe and the UK in 2025, with commercialization planned through strategic partnerships [7].

Core Viewpoint - Synergy CHC Corp. has announced a public offering of 1,750,000 shares at a price of $2.50 per share, aiming for gross proceeds of $4.375 million before expenses [1] Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 262,500 shares at the same public offering price [1] - The expected closing date for the offering is August 27, 2025, pending customary closing conditions [1] - The company will issue warrants to the underwriter for the purchase of up to 52,500 shares, which can increase to 60,375 shares if the over-allotment is exercised [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2] Group 3: Company Overview - Synergy CHC Corp. specializes in consumer health and wellness products, with flagship brands including FOCUSfactor® and Flat Tummy® [7] - FOCUSfactor® is a clinically studied brain health supplement with a 25-year legacy, distributed in major retailers across the U.S., Canada, and the U.K. [7] - The company is experiencing growth and expanding into new markets, with recent retail successes expected to drive gains in late 2025 [7]

Core Viewpoint - Unitil Corporation has announced a public offering of 1,393,355 shares of common stock priced at $46.65 per share, expected to close on August 18, 2025 [1]. Group 1: Offering Details - The underwriters have an option to purchase an additional 209,003 shares at the public offering price, minus underwriting discounts and commissions [2]. - The net proceeds from the offering will be used for equity capital contributions to regulated utility subsidiaries, repayment of outstanding indebtedness, and general corporate purposes [3]. - Wells Fargo Securities, LLC and Scotia Capital (USA) Inc. are acting as active bookrunners for the offering, with Janney Montgomery Scott LLC as a bookrunner [4]. Group 2: Company Overview - Unitil Corporation provides energy services, delivering electricity and natural gas in New England, serving approximately 109,400 electric customers and 97,600 natural gas customers [6].